Jun Feng

This inventor holds 85 USPTO granted patents and 21 published patent applications, plus 3 CIPO patents and 17 EPO patents, primarily in Cancer Therapeutics (CPC class C07D403-04). Top assignees: Araxes Pharma LLC, Takeda Pharmaceutical Company Limited, Kura Oncology, Inc.. Active years: 2003-2026.

USPTO Granted Patents = 85 (Patent Applications = 21)

% Patents Active = 68.2

CIPO Patents = 3 (Patent Applications = 12)

EPO Patents = 17 (Patent Applications = 43)

Average Co-Inventor Count = 6.3

ph-index = 18

Forward Citations = 952(Granted Patents)

Forward Citations (Not Self Cited) = 292(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

La Mesa, CA (US) (2003)
Carlsbad, CA (US) (2004 - 2013)
La Jolla, CA (US) (2019)
San Diego, CA (US) (2012 - 2024)

Company Filing History:

Takeda Pharmaceutical Company Limited

Takeda San Diego, Inc.

patents

5. 6 out of 3,523

University of Michigan

Janssen Biotech, Inc.

Agouron Pharmaceuticals, Inc.

Takeda California, Inc.

patents

13. 1 out of 3

Takeda Pharmaceutical Company Limied

patents

where one patent can have more than one assignee

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

KRAS G12C

Covalent Inhibitors

Quinazoline Compounds

Cancer Treatment

Substituted Piperazines

Thienopyrimidine

Heterocyclic Compounds

Inhibitors of RAS

Fused Bicyclic

Tricyclic Pyridones

Modulators of Mutant KRAS

Menin-MLL Interaction

85 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12551530 - IMMUNE CELL FUNCTION (2026-02-17),

2. RE50527 - Covalent inhibitors of KRAS G12C (2025-08-12),

3. RE50490 - Substituted quinazoline compounds and methods of use thereof (2025-07-15),

4. 12234244 - Substituted piperazines as inhibitors of KRAS G12C (2025-02-25),

5. 12162893 - Tricyclic pyridones and pyrimidones (2024-12-10),

6. 12134620 - Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer (2024-11-05),

7. 11878985 - Substituted quinazolines as inhibitors of KRAS G12C (2024-01-23),

8. 11845761 - Tricyclic pyridones and pyrimidones (2023-12-19),

9. RE49687 - Thienopyrimidine and thienopyridine compounds and methods of use thereof (2023-10-10),

10. 11639346 - Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS (2023-05-02),

11. 11542248 - Methods and compositions for inhibiting the interaction of menin with MLL proteins (2023-01-03),

12. 11377441 - Covalent inhibitors of KRAS (2022-07-05),

13. 11358959 - Benzothiophene and benzothiazole compounds and methods of use thereof (2022-06-14),

14. 11279689 - 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer (2022-03-22),

15. 11274093 - Fused bicyclic benzoheteroaromatic compounds and methods of use thereof (2022-03-15),

Title: The Innovative Journey of Jun Feng

Introduction: Jun Feng, a talented inventor based in San Diego, CA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Jun Feng holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise and creativity.

Career Highlights: With a background in engineering and a passion for problem-solving, Jun Feng has successfully developed cutting-edge solutions that have revolutionized various industries. His commitment to innovation has earned him recognition as a leading figure in the tech world.

Collaborations: Throughout his career, Jun Feng has collaborated with top research institutions, universities, and tech companies to further advance his inventions. His ability to work effectively in multidisciplinary teams has led to the successful implementation of his ideas.

Conclusion: Jun Feng's relentless pursuit of innovation and his remarkable contributions to the world of technology make him a true visionary. His work continues to inspire aspiring inventors and shape the future of technological advancements.